Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 14/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 11/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 11/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 11/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 11/20 | 1.00 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031616 | 1.00 | CHRNA4 (1.00) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12858710 | 0.84 | CHRNA4 (1.00) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL584394 | 0.84 | CHRNA4 (1.00) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14676930 | 0.83 | CHRNB2 (0.71) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17888324 | 0.83 | CHRNA4 (0.71) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7094723 | 0.83 | CHRNB2 (1.00) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17888337 | 0.83 | CHRNA4 (0.71) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17061691 | 0.83 | CHRNA4 (0.71) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL15618170 | 0.81 | CHRNA4 (0.69) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21078273 | 0.80 | CHRNA4 (0.67) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | CCL5, CCR5, CXCL10 | CHRNA4 4569/4885CHRNB2 4444/4885CHRNB4 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.